Insider Trading Alert - BSX, VNDA, RLGY, SNDK And VRTX Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Nov. 21, 2013, 155 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $250.02 to $153,391,332.00.

Highlighted Stocks Traded by Insiders:

Boston Scientific (BSX) - FREE Research Report

Pratt Timothy A. who is EVP, GC & Chief Admin Officer at Boston Scientific sold 20,132 shares at $11.94 on Nov. 21, 2013. Following this transaction, the EVP, GC & Chief Admin Officer owned 119,011 shares meaning that the stake was reduced by 14.47% with the 20,132 share transaction.

Historical insider transactions for Boston Scientific go as follows:

  • 4-Week # shares sold: 150,436
  • 12-Week # shares sold: 150,436
  • 24-Week # shares sold: 247,809

The average volume for Boston Scientific has been 14.3 million shares per day over the past 30 days. Boston Scientific has a market cap of $16.0 billion and is part of the health care sector and health services industry. Shares are up 108.2% year to date as of the close of trading on Thursday.

Boston Scientific Corporation develops, manufactures, and markets medical devices used in various interventional medical specialties worldwide. Currently there are 4 analysts that rate Boston Scientific a buy, no analysts rate it a sell, and 16 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BSX - FREE

TheStreet Quant Ratings rates Boston Scientific as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, compelling growth in net income, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Boston Scientific Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Vanda Pharmaceuticals (VNDA) - FREE Research Report

Polymeropoulos Mihael Hristos who is President and CEO at Vanda Pharmaceuticals sold 8,928 shares at $12.07 on Nov. 21, 2013. Following this transaction, the President and CEO owned 471,636 shares meaning that the stake was reduced by 1.86% with the 8,928 share transaction.

Kelly James Patrick who is SVP, CFO, Sec & Treasurer at Vanda Pharmaceuticals sold 3,348 shares at $12.07 on Nov. 21, 2013. Following this transaction, the SVP, CFO, Sec & Treasurer owned 28,816 shares meaning that the stake was reduced by 10.41% with the 3,348 share transaction.

The shares most recently traded at $11.80, down $0.27, or 2.31% since the insider transaction.

The average volume for Vanda Pharmaceuticals has been 1.5 million shares per day over the past 30 days. Vanda Pharmaceuticals has a market cap of $385.7 million and is part of the health care sector and drugs industry. Shares are up 224.59% year to date as of the close of trading on Thursday.

Vanda Pharmaceuticals, Inc., a biopharmaceutical company, offers development and commercialization of products for the treatment of central nervous system disorders. Currently there are 4 analysts that rate Vanda Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on VNDA - FREE

TheStreet Quant Ratings rates Vanda Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income and weak operating cash flow. Get the full Vanda Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Realogy Holdings (RLGY) - FREE Research Report

Zipf Bruce who is Pres/CEO, NRT LLC at Realogy Holdings sold 25,000 shares at $45.67 on Nov. 21, 2013. Following this transaction, the Pres/CEO, NRT LLC owned 58,178 shares meaning that the stake was reduced by 30.06% with the 25,000 share transaction.

The shares most recently traded at $46.99, up $1.32, or 2.82% since the insider transaction. Historical insider transactions for Realogy Holdings go as follows:

  • 4-Week # shares sold: 29,346
  • 12-Week # shares sold: 29,346
  • 24-Week # shares sold: 86,867

The average volume for Realogy Holdings has been 2.3 million shares per day over the past 30 days. Realogy Holdings has a market cap of $6.5 billion and is part of the financial sector and real estate industry. Shares are up 9.8% year to date as of the close of trading on Thursday.

Realogy Holdings Corp., through its subsidiaries, provides real estate and relocation services in the United States and internationally. The company has a P/E ratio of 2.5. Currently there are 5 analysts that rate Realogy Holdings a buy, 1 analyst rates it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on RLGY - FREE

TheStreet Quant Ratings rates Realogy Holdings as a sell. The company's weaknesses can be seen in multiple areas, such as its generally high debt management risk and poor profit margins. Get the full Realogy Holdings Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

SanDisk (SNDK) - FREE Research Report

Lego Catherine P who is Director at SanDisk sold 6,000 shares at $67.39 on Nov. 21, 2013. Following this transaction, the Director owned 264,254 shares meaning that the stake was reduced by 2.22% with the 6,000 share transaction.

The shares most recently traded at $67.00, down $0.39, or 0.59% since the insider transaction. Historical insider transactions for SanDisk go as follows:

  • 12-Week # shares sold: 16,611
  • 24-Week # shares sold: 16,611

The average volume for SanDisk has been 4.1 million shares per day over the past 30 days. SanDisk has a market cap of $15.0 billion and is part of the technology sector and computer hardware industry. Shares are up 54.95% year to date as of the close of trading on Thursday.

Sandisk Corporation designs, develops, manufactures, and markets flash storage card products that are used in various consumer electronics products. The stock currently has a dividend yield of 1.36%. The company has a P/E ratio of 17.5. Currently there are 15 analysts that rate SanDisk a buy, 1 analyst rates it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SNDK - FREE

TheStreet Quant Ratings rates SanDisk as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, compelling growth in net income, good cash flow from operations and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full SanDisk Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Vertex Pharmaceuticals (VRTX) - FREE Research Report

Sachs Bruce I who is Director at Vertex Pharmaceuticals sold 8,300 shares at $65.28 on Nov. 21, 2013. Following this transaction, the Director owned 54,810 shares meaning that the stake was reduced by 13.15% with the 8,300 share transaction.

The shares most recently traded at $67.07, up $1.79, or 2.67% since the insider transaction. Historical insider transactions for Vertex Pharmaceuticals go as follows:

  • 4-Week # shares sold: 993
  • 12-Week # shares sold: 30,010
  • 24-Week # shares sold: 60,451

The average volume for Vertex Pharmaceuticals has been 2.6 million shares per day over the past 30 days. Vertex Pharmaceuticals has a market cap of $15.2 billion and is part of the health care sector and drugs industry. Shares are up 58.07% year to date as of the close of trading on Thursday.

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. Currently there are 12 analysts that rate Vertex Pharmaceuticals a buy, no analysts rate it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on VRTX - FREE

TheStreet Quant Ratings rates Vertex Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full Vertex Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Data for this article provided by Zacks Investment Research

null

More from Markets

Global Stocks Hold Gains as North Korea Response on Talks Soothes Nerves

Global Stocks Hold Gains as North Korea Response on Talks Soothes Nerves

Canopy Growth Lets Down Eager Pot Investors; PayPal Keeps Dominating -- ICYMI

Canopy Growth Lets Down Eager Pot Investors; PayPal Keeps Dominating -- ICYMI

Dow, S&P 500 and Nasdaq Tumble After Trump Calls Off North Korea Summit

Dow, S&P 500 and Nasdaq Tumble After Trump Calls Off North Korea Summit

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists